The role of immune activation in contributing to vascular dysfunction and the pathophysiology of hypertension during preeclampsia

Minerva Ginecologica

Volumn 62, Issue 2, 2010, Pages 105-120

  Lamarca, B ^a  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

Author keywords

Hypertension; Placenta; Preeclampsia

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTIBODY; ANGIOTENSIN II; AUTOANTIBODY; ENDOTHELIN; HYDROXYPROGESTERONE; INTERLEUKIN 6; NITRIC OXIDE; PROGESTERONE; PROSTACYCLIN; REACTIVE OXYGEN METABOLITE; RECEPTOR ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 1; ANGIOGENIC PROTEIN; CYTOKINE;

ANTIHYPERTENSIVE ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARACHIDONIC ACID METABOLISM; B LYMPHOCYTE; CARDIOVASCULAR FUNCTION; CAUSE OF DEATH; CHRONIC INFLAMMATION; CYTOKINE PRODUCTION; ENDOTHELIAL DYSFUNCTION; HUMAN; HYPERTENSION; IMMUNOPATHOLOGY; INFLAMMATORY CELL; ISCHEMIA; MATERNAL MORTALITY; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PERINATAL MORBIDITY; PLACENTA CIRCULATION; PLACENTA ISCHEMIA; PREECLAMPSIA; PREMATURITY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; T LYMPHOCYTE; UTERINE ARTERY; VASCULAR DISEASE; VASCULAR ENDOTHELIUM; BLOOD VESSEL; FEMALE; IMMUNOLOGY; PHYSIOLOGY; PRE-ECLAMPSIA; PREGNANCY;

ANGIOGENIC PROTEINS; B-LYMPHOCYTES; BLOOD VESSELS; CYTOKINES; ENDOTHELINS; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPERTENSION; NITRIC OXIDE; OXIDATIVE STRESS; PRE-ECLAMPSIA; PREGNANCY; PROGESTERONE; T-LYMPHOCYTES;

EID: 77954717745     PISSN: 00264784     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (99)

1. Roberts JM, Pearson G, Cutler J, Lindheimer M. Summary of the NHLBI Working Group on Research on Hypertension During Pregnancy. Hypertension. 2003;41:437-445. (Pubitemid 36314613)
2. Thadhani RI, Johnson RJ, Karumanchi SA. Hypertension during pregnancy: a disorder begging for pathophysiological support. Hypertension 2005;46:1250-1.
3. Roberts JM, Gammill H. Insulin resistance in preeclampsia. Hypertension 2006;47:341-2.
4. Roberts JM, Gammill HS. Preeclampsia: recent insights. Hypertension 2005;46:1243-9.
5. Germain AM, Romanik MC, Guerra I, Solari S, Reyes MS, Johnson RJ et al. Endothelial dysfunction: a link among preeclampsia, recurrent pregnancy loss, and future cardiovascular events? Hypertension 2007;49:90-5.
6. Blaauw J, Graaff R, van Pampus MG, van Doormaal JJ, Smit AJ, Rakhorst G, Aarnoudse JG et al. Changes in endothelial function precede the clinical disease in women in whom preeclampsia develops in response: endothelial function and preeclampsia. Hypertension 2006;47:e14-e15.
7. Khan F, Belch JJF, Macleod M, Mires G. Changes in endothelial function precede the clinical disease in women in whom preeclampsia develops. Hypertension 2005;46:1123-8.
8. Myers J, Mires G, Macleod M, Baker P. In preeclampsia, the circulating factors capable of altering in vitro endothelial function precede clinical disease. Hypertension 2005;45:258-63.
9. Chambers JC, Fusi L, Malik IS, Haskard DO, De Swiet M, Kooner JS. Association of Maternal Endothelial Dysfunction with Preeclampsia. JAMA 2001;285:1607-12.
10. Granger JP, Alexander BT, Llinas MT, Bennett WA, Khalil RA. Pathophysiology of hypertension during preeclampsia: Linking placental ischemia with endothelial dysfunction. Hypertension 2001;38(3 Pt 2):718-22.
11. Granger JP, Alexander BT, Bennett WA, Khalil RA. Pathophysiology of pregnancy-induced hypertension. Microcirculation 2002;9:147-60.
12. Roberts JM, Von Versen-Hoeynck F. Maternal fetal/placental interactions and abnormal pregnancy outcomes. Hypertension 2007;49:15-6.
13. Sabour S, Franx A, Rutten A, Grobbee DE, Prokop M, Bartelink ML et al. High blood pressure in pregnancy and coronary calcification. Hypertension 2007;49:813-7.
14. Mello G, Parretti E, Marozio L, Pizzi C, Lojacono A, Frusca T et al. Thrombophilia is significantly associated with severe preeclampsia: results of a large-scale, case-controlled study. Hypertension 2005b;46:1270-4.
15. Irgens HU, Reisater L, Irgens LM, Lie RT, Roberts JM. Long term mortality of mothers and fathers after preeclampsia: population based cohort study Pre-eclampsia and cardiovascular disease later in life: who is at risk? BMJ 2001;323:1213-7.
16. Poston L. Endothelial dysfunction in preeclampsia. Pharmacological Reports 2006;69-74.
17. McMaster MT, Ahou Y, Fisher SJ. Abnormal placentation and the syndrome of preeclampsia. Semin Nephrol 2004;24:540-7.
18. Sharma A, Satyam A, Sharma JB. Leptin, IL-10, and inflammatory markers (TNF-alpha, IL-6 and IL-8) in preeclamptic, normotensive pregnant and healthy non-pregnant women. Am J Reprod Immunol 2007;58:21-30.
19. Girardi G, Yarilin D, Thurman JM, Holers VM, Salmon JE. Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. JEM 2006;203:2164-75.
20. Conrad KP, Benyo DF. Placental cytokines and the pathogenesis of preeclampsia. Am J Reprod Immunol 1997;37:240-9.
21. Wang Y, Walsh SW. TNF alpha concentrations and mRNA expression are increased in preeclamptic placentas. J Reprod Immunol 1996;32:157-69.
22. Freeman DJ, McManus F, Brown EA, Cherry L, Norrie J, Ramsay JE et al. Short- and long-term changes in plasma inflammatory markers associated with preeclampsia. Hypertension 2004;44:708-14.
23. Armanini D, Calo LA. Aldosterone, inflammation, and preeclampsia. Hypertension 2005;45:e10.
24. LaMarca BB, Bennett WA, Alexander BT, Cockrell K, Granger JP. Hypertension produced by reductions in uterine perfusion in the pregnant rat: role of tumor necrosis factor-{alpha}. Hypertension 2005a;46:1022-5.
25. LaMarca BB, Cockrell K, Sullivan E, Bennett W, Granger JP. Role of endothelin in mediating tumor necrosis factor-induced hypertension in pregnant rats. Hypertension 2005b;46:82-6.
26. Leik C, Walsh SW. Neutrophils infiltrate resistance-sized vessels of subcutaneous fat in women with preeclampsia. Hypertension 2004;44:72-7.
27. Gadonski G, LaMarca BB, Sullivan E, Bennett W, Chandler D, Granger JP. Hypertension produced by reductions in uterine perfusion in the pregnant rat: role of interleukin 6. Hypertension 2006;48:711-6.
28. Abbus A. Cellular and molecular immunology. Lichtman A, editor. 5. Philadelphia, Pennsylvania: Elsevier; 2009.
29. Wulff H, Pennington M. Targeting effector memory T-cells with Kv1.3 blockers. Curr Opin Drug Discov Devel 2007;10:438-45.
30. Rutella S. Granulocyte colony-stimulating factor for the induction of T-cell tolerance. Transplantation 2007;84(1 Suppl):S26-S30.
31. Santner-Nanan B, Peek MJ, Khanam R, Richarts L, Zhu E, Fazekas de St Groth B et al. Systemic increase in the ratio between Foxp3+ and IL-17-Producing CD4+T cells in healthy pregnancy but not in preeclampsia. J Immunol 2009;183:7023-30.
32. Heo YJ, Joo YB, Oh HJ, Park MK, Heo YM, Cho ML et al. IL-10 suppresses Th17 cells and promotes regulatory T cells in the CD4(+) T cell population of rheumatoid arthritis patients. Immunol Lett 2010;127:150-6.
33. Hasegawa M, Fujimoto M, Takehara K, Sato S. Pathogenesis of systemic sclerosis: altered B cell function is the key linking systemic autoimmunity and tissue fibrosis. J Dermatol Sci 2005;39:1-7.
34. Panayi GS. B cells: a fundamental role in the pathogenesis of rheumatoid arthritis? Rheumatology (Oxford) 2005;44 Suppl 2:ii3-ii7.
35. Hubel CA, Wallukat G, Wolf M, Herse F, Rajakumar A, Roberts JM et al. Agonistic angiotensin II type 1 receptor autoantibodies in postpartum women with a history of preeclampsia. Hypertension 2007;49:612-7.
36. Conrad KP, Kerchner LJ, Mosher MD. Plasma and 24-h NO(x) and cGMP during normal pregnancy and preeclampsia in women on a reduced NO(x) diet. Am J Physiol 1999;277:F48-F57.
37. Taylor RN, de Groot CJ, Cho YK, Lim KH. Circulating factors as markers and mediators of endothelial cell dysfunction in preeclampsia. Semin Reprod Endocrinol 1998;16:17-31.
38. Serrano NC, Casas JP, Diaz LA, Paez C, Mesa CM, Cifuentes R et al. Endothelial NO synthase genotype and risk of preeclampsia: a multicenter case-control study. Hypertension 2004;44:702-7.
39. McCord N, Ayuk P, McMahon M, Boyd RCA, Sargent I, Redman C. System y+ Arginine Transport and NO Production in Peripheral Blood Mononuclear Cells in Pregnancy and Preeclampsia. Hypertension 2006;47:109-15.
40. Noris M, Todeschini M, Cassis P, Pasta F, Cappellini A, Bonazzola S et al. L-arginine depletion in preeclampsia orients nitric oxide synthase toward oxidant species. Hypertension 2004;43:614-22.
41. Alexander BT, Kassab SE, Miller MT, Abram SR, Reckelhoff JF, Bennett WA et al. Reduced uterine perfusion pressure during pregnancy in the rat is associated with increases in arterial pressure and changes in renal nitric oxide. Hypertension 2001;37:1191-5.
42. Alexander BT, Llinas MT, Kruckeberg WC, Granger JP. L-arginine attenuates hypertension in pregnant rats with reduced uterine perfusion pressure. Hypertension 2004;43:832-6.
43. Crews JK, Herrington JN, Granger JP, Khalil RA. Decreased endothelium-dependent vascular relaxation during reduction of uterine perfusion pressure in pregnant rat. Hypertension. 2000;35:367-72.
44. Walsh SW. Maternal-placental interactions of oxidative stress and antioxidants in preeclampsia. Semin Reprod Endocrinol 1998;16:93-104.
45. Tsukimori K, Fukushima K, Tsushima A, Nakano H. Generation of reactive oxygen species by neutrophils and endothelial cell injury in normal and preeclamptic pregnancies. Hypertension 2005;46:696-700.
46. Tsukimori K, Nakano H, Wake N. Difference in neutrophil superoxide generation during pregnancy between preeclampsia and essential hypertension. Hypertension 2007;49:1436-41.
47. Raijmakers MTM, Dechend R, Poston L. Oxidative Stress and Preeclampsia: Rationale for Antioxidant Clinical Trials. Hypertension 2004;44:374-80.
48. Rumbold AR, Crowther CA, Haslam RR, Dekker GA, Robinson JS, ACTS Study Group. Vitamins C and E and the risks of preeclampsia and perinatal complications. New Engl J Med 2006;354:1796-806.
49. Poston L, Briley AL, Seed PT, Kelly FJ, Sherman AH. Vitamin C and vitamin E in pregnant women at risk for pre-eclampsia (VIP trial): randomised placebo-controlled trial. Lancet 2006;367:1145-54.
50. Sedeek M, Gilbert JS, LaMarca B, Shollok M, Chandler DL, Wang Y et al. Role of reactive oxygen species in hypertension produced by reduced uterine perfusion in pregnant rats. Am J Hypertens 2008;21:1152-6.
51. Taylor RN, Varma M, Teng NN, Roberts JM. Women with preeclampsia have higher plasma endothelin levels than women with normal pregnancies. J Clin Endocrinol Metab 1990;71:1675-7.
52. Nova A, Sibai BM, Barton JR, Mercer BM, Mitchell MD. Maternal plasma level of endothelin is increased in preeclampsia. Am J Obstet Gynecol 1991;165:724-7.
53. Alexander BT, Rinewalt AN, Cockrell KL, Massey MB, Bennett WA, Granger JP. Endothelin type a receptor blockade attenuates the hypertension in response to chronic reductions in uterine perfusion pressure. Hypertension 2001;37:485-9.
54. Roberts L, LaMarca B, Fournier L, Bain J, Cockrell K, Granger JP. Enhanced endothelin synthesis by endothelial cells exposed to sera from pregnant rats with decreased uterine perfusion. Hypertension 2006;47:615-8.
55. Walsh SW. Eicosanoids in preeclampsia. Prostaglandins Leukot Essent Fatty Acids 2004;70:223-32.
56. Woods LL. Importance of prostaglandins in hypertension during reduced uteroplacental perfusion pressure. Am J Physiol 1989;257:R1558-R1561.
57. Llinas MT, Alexander BT, Seedek M, Abram SR, Crell A, Granger JP. Enhanced thromboxane synthesis during chronic reductions in uterine perfusion pressure in pregnant rats. Am J Hypertens 2002;15:793-7.
58. Llinas MT, Alexander BT, Capparelli MF, Carroll MA, Granger JP. Cytochrome P-450 inhibition attenuates hypertension induced by reductions in uterine perfusion pressure in pregnant rats. Hypertension 2004;43:623-8.
59. Rajakumar A, Michael HM, Rajakumar PA, Shibata E, Hubel CA, Karumanchi SA et al. Extra-placental expression of vascular endothelial growth factor receptor-1, (Flt-1) and soluble Flt-1 (sFlt-1), by peripheral blood mononuclear cells (PBMCs) in normotensive and preeclamptic pregnant women. Placenta 2005;26:563-73.
60. Rana S, Karumanchi SA, Levine RJ, Venkatesha S, Rauh-Hain JA, Tamez H et al. Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension 2007;50:137-42.
61. Lindheimer MD, Romero R. Emerging roles of antiangiogenic and angiogenic proteins in pathogenesis and prediction of preeclampsia. Hypertension 2007;50:35-6.
62. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003;111:649-58.
63. Lu F, Longo M, Tamayo E, Maner W, Al-Hendy A, Anderson GD et al. The effect of over-expression of sFlt-1 on blood pressure and the occurrence of other manifestations of preeclampsia in unrestrained conscious pregnant mice. Am J Obstet Gynecol 2007;196:396.
64. Li Z, Zhang Y, Ying Ma J, Kapoun AM, Shao Q, Kerr I et al. Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia. Hypertension 2007;50:686-92.
65. Gilbert JS, Babcock SA, Granger JP. Hypertension produced by reduced uterine perfusion in pregnant rats is associated with increased soluble fms-like tyrosine kinase-1 expression. Hypertension 2007;50:1142-7.
66. Makris A, Thornton C, Thompson J, Thomson S, Martin R, Ogle R et al. Uteroplacental ischemia results in proteinuric hypertension and elevated sFLT-1. Kidney Int 2007;71:977-84.
67. Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med. 2006;12:642-9.
68. Shah DM. Role of the renin-angiotensin system in the pathogenesis of preeclampsia. Am J Physiol Renal Physiol 2005;288:F614-F625.
69. Xia Y, Ramin SM, Kellems RE. Potential roles of angiotensin receptor-activating autoantibody in the pathophysiology of preeclampsia. Hypertension 2007;50:269-75.
70. Herse F, Dechend R, Harsem NK, Wallukat G, Janke J, Qadri F et al. Dysregulation of the circulating and tissue-based renin-angiotensin system in preeclampsia. Hypertension 2007;49:604-11.
71. Levesque S, Moutquin JM, Lindsay C, Roy MC, Rousseau F. Implication of an AGT Haplotype in a Multigene Association Study With Pregnancy Hypertension. Hypertension 2004;43:71-8.
72. Mello G, Parretti E, Fatini C, Riviello C, Gensini F, Marchionni M et al. Low-molecular-weight heparin lowers the recurrence rate of preeclampsia and restores the physiological vascular changes in angiotensin-converting enzyme dd women. Hypertension 2005a;45:86-91.
73. Wallukat G, Homuth V, Fischer T, Lindschau C, Horstkamp B, Jupner A et al. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J Clin Invest 1999;103:945-52.
74. Dechend R, Gratze P, Wallukat G, Shagdarsuren E, Plehm R, Brasen JH et al. Agonistic autoantibodies to the at1 receptor in a transgenic rat model of preeclampsia. Hypertension 2005;45:742-6.
75. LaMarca B, Parrish M, Fournier Ray L, Murphy SR, Roberts L, Glover Gerd Wallukat P et al. Hypertension in response to autoantibodies to the angiotensin II type I receptor (AT1-AA) in pregnant rats: Role of endothelin-1. Hypertension 2009;54:905-9.
76. LaMarca BB, Wallukat G, Llinas M, Herse F, Dechend R, Granger JP. Elevated agonistic autoantibodies to the angiotensin type 1 (AT1-AA) receptor in response to placental ischemia and TNF alpha in pregnant rats. Hypertension 20058;52:7-11.
77. Walther T, Wallukat G, Jank A, Bartel S, Schultheiss HP, Faber R et al. Angiotensin II Type 1 receptor agonistic antibodies reflect fundamental alterations in the uteroplacental vasculature. Hypertension 2005;46:1275-9.
78. Gadonski G, LaMarca BB, Sullivan E, Bennett W, Chandler D, Granger JP. Hypertension produced by reductions in uterine perfusion in the pregnant rat: Role of Interleukin-6. Hypertension 2006;48:711.
79. Granger JP, LaMarca BBD, Cockrell K, Sedeek M, Balzi C, Chandler D et al. Reduced uterine perfusion pressure (RUPP) model for studying cardiovascular-renal dysfunction in response to placental ischemia. Methods Mol Med 2006;122:383-92.
80. LaMarca BB, Speed J, Fournier L, Babcock SA, Berry H, Cockrell K et al. Hypertension in response to chronic reductions in uterine perfusion in pregnant rats: Effect of TNF alpha blockade. Hypertension 2008;52:1-5.
81. Shimizu A, Masuda Y, Mori T, Kitamura H, Ishizaki M, Sugisaki Y et al. Vascular endothelial growth factor165 resolves glomerular inflammation and accelerates glomerular capillary repair in rat anti-glomerular basement membrane glomerulonephritis. J Am Soc Nephrol 2004;15:2655-65.
82. Miyamoto K, Kitamoto Y, Tokunaga H, Takeya M, Ezaki T, Imamura T et al. Protective effect of vascular endothelial growth factor/vascular permeability factor 165 and 121 on glomerular endothelial cell injury in the rat. Lab Invest 2004;84:1126-36.
83. Hara A, Wada T, Furuichi K, Sakai N, Kawachi H, Shimizu F et al. Blockade of VEGF accelerates proteinuria, via decrease in nephrin expression in rat crescentic glomerulonephritis. Kidney Int 2006;69:1986-95.
84. Bujold E, Romero R, Chaiworapongsa T, Kim YM, Kim GJ, Kim MR et al. Evidence supporting that the excess of the sVEGFR-1 concentration in maternal plasma in preeclampsia has a uterine origin. J Matern Fetal Neonatal Med 2005;18:9-16.
85. Krysiak O, Bretschneider A, Zhong E, Webb J, Hopp H, Verlohren S et al. Soluble vascular endothelial growth factor receptor-1 (sFLT-1) mediates downregulation of FLT-1 and prevents activated neutrophils from women with preeclampsia from additional migration by VEGF. Circ Res 2005;97:1253-61.
86. Nevo O, Soleymanlou N, Wu Y et al. Increased expression of sFlt-1 in in vivo and in vitro models of human placental hypoxia is mediated by HIF-1. Am J Physiol Regul Integr Comp Physiol 2006; 291:R1085-R1093.
87. Maruotti N, Cantatore FP, Crivellato E, Vacca A, Ribatti D. Angiogenesis in rheumatoid arthritis. Histol Histopathol 2006;557-66.
88. Eubank TD, Roberts R, Galloway M, Wang Y, Cohn DE, Marsh CB. GM-CSF induces expression of soluble VEGF receptor-1 from human monocytes and inhibits angiogenesis in mice. Immunity 2004;21:831-42.
89. Tam Tam K, Wallace K , RutlandS, Mott K, Weimer A, Martin JN Jr, LaMarca B. Placental ischemia triggers immune activation as leukocyte overproduction of SFLT-1: a step in the pathogenesis of preeclampsia? Presented at the 30th Annual Meeting: The Pregnancy Meeting Society of Maternal Fetal Medicine, February. 2, 2010, Chicago IL.
90. .) during pregnancy. Presented at the Central Association of Obstetrics and Gynecology meeting Oct 26-28 in Maui, Hawaii.
91. Speed J, Fournier L, Cockrell K, Dechend R, Granger J, LaMarca B. IL-6 induced hypertension in pregnant rats is associated with production agonistic autoantibodies to the angiotensin II type I receptor. Presented at Experimental Biology, April 5 2009, New Orleans, LA.
92. Dechend R, Viedt C, Muller DN, Ugele B, Brandes RP, Wallukat G et al. AT1 receptor agonistic antibodies from preeclamptic patients stimulate NADPH oxidase. Circulation 2003;107:1632-9.
93. Parrish M, Fournier L, Arany M, Weimer A, Cockrell K, Dechend R et al. Hypertension in response to agonistic autoantibodies to the angiotensin II type I receptor (AT1-AA): role of reactive oxygen species (ROS) Presented at the 30th Annual Meeting: The Pregnancy Meeting Society of Maternal Fetal Medicine, February. 22010, Chicago IL.
94. Siddiqui AH, Irani RA, Blackwell SC, Ramin SM, Kellems RE, Xia Y. Angiotensin receptor agonistic autoantibody is highly prevalent in preeclampsia. Correlation with disease severity. Hypertension 2010;55:236-7.
95. Stepan H, Walther T. Questionable role of the angiotensin II receptor subtype 1 autoantibody in the pathogenesis of preeclampsia. Hypertension 2007;50:e3.
96. Stepan H, Faber R, Wessel N, Wallukat G, Schultheiss HP, Walther T. Relation between circulating angiotensin II Type 1 receptor agonistic autoantibodies and soluble fms-Like tyrosine kinase 1 in the pathogenesis of preeclampsia. J Clin Endocrinol Metab 2006;91:2424-7.
97. Sammour MB, El-Kabarity H, Fawzy MM, Schindler AE. Prevention and treatment of pregnancy-induced hypertension (preeclampsia) with progestogens. J Steroid Biochem Mol Biol 2005;97:439-40.
98. Veillon EW Jr, Reiser SD, Parrish MR, Bennett W, Cockrell K, Ray LF et al. 17 OHP blunts the hypertensive response associated with Reductions in Uterine Perfusion Pressure in pregnant rats. J Obstet Gynecol 2009;201:324-9.
99. Reiser SD, Veillon EW, Parrish MR, Bennett W, Cockrell R, Fournier L et al. Effects of 17-hydroxyprogesterone on tumor necrosis factor-alpha-induced hypertension during pregnancy. Am J Hypertens 2009;22:1120-5.